AEON Biopharma Appoints John Bencich as Chief Financial Officer

Veteran biotechnology leader with extensive capital markets experience joins AEON as Company advances lead asset through key regulatory milestonesIRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced the appointment of John Bencich as Chief Financial Officer ...